Once-per-week selinexor, bortezomib, and dexamethasone versus twice-per-week bortezomib and dexamethasone in patients with multiple myeloma (BOSTON): a randomised, open-label, phase 3 trial

• Authors: GROSICKI Sebastian; SIMONOVA Maryana; SPICKA Ivan; POUR Luděk; KRIACHOK Iryrna; GAVRIATOPOULOU Maria; PYLYPENKO Halyna; AUNER Holger W; LELEU Xavier; DORONIN Vadim; USENKO Ganna; BAHLIS Nizar J; HAJEK Roman; BENJAMIN Reuben; DOLAI Tuphan K; SINHA Dinesh K; VENNER Christopher P; GARG Mamta; GIRONELLA Mercedes; JURCZYSZYN Artur; ROBAK Pawel; GALLI Monica; WALLINGTON-BEDDOE Craig; RADINOFF Atanas; SALOGUB Galina; DON; STEVENS; BASU Supratik; LIBERATI Anna M; QUACH Hang; GORANOVA-MARINOVA Vesselina S; BILA Jelena; KATODRITOU Eirini; OLIYNYK Hanna; KORENKOVA Sybiryna; KUMAR Jeevan; JAGANNATH Sundar; MOREAU Phillipe; LEVY Moshe; WHITE Darrell; GATT Moshe E; FACON Thierry; MATEOS Maria V; CAVO Michele; REECE Donna; JR Larry D Anderson; SAINT-MARTIN Jean-Richard; JEHA Jacqueline; ANITA; JOSHI; CHAI Yi; LI Lingling; PEDDAGALI Vishnuvardhan; ARAZY Melina; SHAH Jatin; SHACHAM Sharon; KAUFFMAN Michael G; MELETIOS; DIMOPOULOS; RICHARDSON Paul G; DELIMPASI Sosana
• Year of publication: 2020
• Type: Article in Periodical
• Magazine / Source: Lancet
• MU Faculty or unit: Faculty of Medicine
• Web: https://www.sciencedirect.com/science/article/pii/S0140673620322923?via%3Dihub
• Doi: http://dx.doi.org/10.1016/S0140-6736(20)32292-3
• Description: Selinexor combined with dexamethasone has shown activity in patients with heavily pre-treated multiple myeloma. In a phase 1b/2 study, the combination of oral selinexor with bortezomib (a proteasome inhibitor) and dexamethasone induced high response rates with low rates of peripheral neuropathy, the main dose-limiting toxicity of bortezomib. We aimed to evaluate the clinical benefit of weekly selinexor, bortezomib, and dexamethasone versus standard bortezomib and dexamethasone in patients with previously treated multiple myeloma.